Treatment strategies of recurrent hepatitis C after liver transplantation based on IL28B singlencleotide polymorphism.

日本对丙型肝炎病毒阳性受体进行了一项全国性的活体供肝移植(LDLT)调查。在研究收集的514名接受者中，361名患者在肝移植后接受了抗病毒治疗。VR率为64.1%，SVR率为38.3%。有SVR的患者5年和10年累积生存率(94.1%和83.0%)明显高于无SVR的患者(79.7%和60.8%)。受者和供者均存在主等位基因(TT)，对应的SVR为58.2%。受者和供者的等位基因(TG或GG)与SVR的符合率分别为15.7%、16.7%和28.5%。多因素分析显示，受者或供者的IL28B基因多态是发生SVR的独立因素。综上所述，我们的研究表明，供者和受者的IL28B基因都与移植物存活和对干扰素/RBV治疗的反应密切相关。

A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus-positive recipients was performed in Japan. Of 514 recipients collected in the study, 361 patients underwent antiviral treatment after liver transplantation. VR rate was 64.1%, and SVR rate was 38.3%. The 5-yr and 10-yr cumulative patient survival with SVR (94.1% and 83.0%) were significantly superior than those without SVR (79.7% and 60.8%). Presence of the major allele (TT) in both the recipient and the donor corresponded to SVR of 58.2%. Presence of the minor allele (TG or GG) in either the recipient or the donor corresponded to SVR of 15.7%, 16.7% and 28.5%. Multivariate analysis revealed that genotype of IL28B polymorphisms in either the recipient or donor was an independent factor for achieving SVR. In conclusion, our study demonstrated that both donor and recipient IL28B genotype were strongly associated with graft survival and response to IFN/RBV therapy for LDLT recipients.